Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Study Details
Study Description
Brief Summary
A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Detailed Description
Bafetinib is a dual protein kinase inhibitor, targeting both bcr/abl and Lyn kinases. B-cell chronic lymphocytic leukemia cells overexpress Lyn kinase compared to normal B lymphocytes as well as acute leukemias (ALL and AML), and inhibition of Lyn kinase induces apoptosis in cultures of B-CLL cells. Thus, bafetinib may stop the growth of B-CLL cells by inhibiting Lyn kinase, the molecule that couples the B cell receptor to downstream signaling.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Bafetinib
|
Drug: bafetinib
250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To evaluate the response rate (complete and partial), in subjects with relapsed or refractory B-Cell CLL [Upto 6 months or disease progression]
Secondary Outcome Measures
- Adverse Events [1 year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years, male or female.
-
B-cell chronic lymphocytic leukemia meeting the WHO criteria.
-
Relapsed or refractory disease with at least one of the following criteria: *progression after at least one course of a purine nucleoside analog (fludarabine phosphate, cladribine, pentostatin)
-
progression after at least one course of an alkylating agent (cyclophosphamide or chlorambucil)
-
relapse within 12 months after at least one course of either a purine nucleoside or an alkylating agent.
-
Capable of providing informed consent and complying with trial procedures.
-
ECOG performance status 0-2.
-
Requires chemotherapy for disease as shown by any of the following criteria:
-
measurable and progressive lymphocytosis
-
measurable and progressive lymphadenopathy (lymph node ≥2 cm in a single diameter)
-
either weight loss ≥10% within the past 6 months or extreme fatigue due to leukemia
-
fevers ≥100.5 degrees F for 2 weeks with no source of infection
-
night sweats with no evidence of infection
-
progressive marrow failure (worsening anemia with hemoglobin <10 gm/dL and/or thrombocytopenia with platelet count <100,000/mm3)
-
massive or progressive splenomegaly (spleen >6 cm below left costal margin).
-
Women must not be able to become pregnant (e.g. post menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. [Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.]
-
Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
-
Accessibility to the site.
Exclusion Criteria:
-
Chemotherapy, antibody therapy, surgery within 4 weeks of study enrollment.
-
Exposure to any investigational agent within 30 days of the Screening Visit.
-
Known CNS disease.
-
Concurrent active malignancies except basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix.
-
Laboratory values: Screening creatinine clearance (calculated by Cockcroft Gault formula) of less than 50 mL/minute, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal, total bilirubin greater than 3 times the upper limit of normal, white blood cell (WBC) count <3500/mm3, absolute neutrophil count <1000/mm3, hematocrit level <33% for females or <35% for males.
-
Clinically evident congestive heart failure >class II of the New York Heart Association (NYHA) guidelines.
-
Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
-
History or signs of active coronary artery disease with or without angina pectoris.
-
Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) <45% of predicted.
-
Known HIV infection.
-
Uncontrolled active, infection.
-
Major surgery within 3 weeks prior to treatment.
-
Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
-
Any condition that in the opinion of the Investigator is unstable and could jeopardize the subject's participation in the study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | City of Hope National Medical Center | Duarte | California | United States | 91010 |
2 | UT M.D. Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- CytRx
Investigators
- Study Director: Daniel Levitt, M.D., Ph.D., CytRx
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BAFETINIB-P2-CLL-01